Novartis Stock Earnings Estimates Raised by Zacks Research

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research boosted their FY2027 earnings per share estimates for Novartis in a research report issued on Friday, September 25th. Zacks Research analyst Team now forecasts that the company will earn $9.75 per share for the year, up from their prior estimate of $9.68. The consensus estimate for Novartis’ current full-year earnings is $8.87 per share. Zacks Research also issued estimates for Novartis’ Q4 2027 earnings at $2.47 EPS.

Several other brokerages have also issued reports on NVS. HSBC upgraded shares of Novartis from a “reduce” rating to a “hold” rating and boosted their target price for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Royal Bank Of Canada started coverage on Novartis in a research note on Tuesday, September 8th. They issued a “sector perform” rating for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft downgraded Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $153.00.

Novartis Price Performance

NYSE NVS opened at $146.95 on Monday. The company has a 50-day moving average price of $151.62 and a 200-day moving average price of $151.15. Novartis has a 52 week low of $121.57 and a 52 week high of $170.46. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $280.40 billion, a P/E ratio of 22.16, a PEG ratio of 2.81 and a beta of 0.45.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

Institutional Investors Weigh In On Novartis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Archer Investment Corp boosted its stake in shares of Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after acquiring an additional 80 shares during the period. Highland Investment Advisors LLC bought a new stake in Novartis during the 2nd quarter valued at approximately $25,000. Evolution Wealth Management Inc. lifted its holdings in Novartis by 552.0% in the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock worth $26,000 after purchasing an additional 138 shares in the last quarter. Atlatl Advisers LLC purchased a new position in Novartis in the 2nd quarter worth approximately $26,000. Finally, Silicon Valley Capital Partners boosted its stake in Novartis by 519.4% in the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after purchasing an additional 161 shares during the period. 13.12% of the stock is owned by institutional investors.

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.